Genomic characterization of aggressiveness in pituitary neuroendocrine tumors

Read full text
Authors: Nesrine Benanteur, Chiara Villa, Fabio Bioletto, Maria Francesca Birtolo, D. De Murat, Julien Masliah-Planchon, Victor Gravrand, Inès Lebib, Mounia Benkhellat, Robin Boëzennec, Stéphanie Allassonnière, Franck Letourneur
+21 more Y. Ruiz Martín, Fidéline Bonnet Serrano, Julian Jacob, Valentin Calugaru, Maxime Barat, Anthony Dohan, Jennifer Arrondeau, Olivier Huillard, Marie-Laure Raffin-Sanson, Jean François Emile, Gérald Raverot, Rossella Libé, Laurence Guignat, Cyril Garcia, L. Groussin, Xavier Bertagna, S. Gaillard, Jérôme Bertherat, Anne Jouinot, Bertrand Baussart, Guillaume Assié
Cited by: 3
References: 33

Abstract

BACKGROUND: Aggressive evolution of PitNETs is rare; metastatic spread is even more. Defining aggressiveness and malignancy is challenging, subsequently hard to predict, and to understand. The aim was to provide a molecular definition of aggressiveness using genomic approaches. METHODS: PitNETs from 206 patients were included. Associations between 9 clinicopathological features of aggressiveness and PitNETs' omics were explored. Omics included transcriptome, DNA methylation, chromosomal alterations, and mutations. Clonal tumor evolution was monitored in 7 patients. RESULTS: Among the 9 clinicopathological features of aggressiveness, only rapid progression, progression after radiotherapy, Ki67/MIB1 proliferation index ≥10%, temozolomide treatment, metastases, and specific death were associated with specific omics signatures, while tumour maximal diameter ≥40 mm, cavernous, and sphenoid invasion were not. The omic signatures associated with these features of aggressiveness overlapped but remained distinct between corticotroph and mammo-somato-thyrotroph lineages. For each lineage, a common signature of aggressiveness was identified, associating a proliferative transcriptome signature and DNA hypermethylation. Alterations in specific genes were associated with aggressive features, including a novel PitNET gene, LRP1B, and known cancer genes (TP53, CDKN2A), while USP8 and GNAS alterations were not. Integration of gene alterations with methylome and transcriptome signatures isolated a subset of molecularly aggressive PitNETs. Molecular signatures were stable during the course of the disease, despite evolution toward aggressiveness and potential clonal divergence. CONCLUSION: This systematic analysis of clinicopathological features of aggressiveness using an integrated multiomic approach establishes a histomolecular definition of aggressiveness in PitNETs. Prospective cohort studies are needed to validate these molecular signatures and establish their prognostic value.

Fields of Study & Subjects

Pituitary Gland Disorders and Treatments Neuroendocrine Tumor Research Advances Adrenal and Paraganglionic Tumors

Publication details

Journal / source
Neuro-Oncology
Publisher
Oxford University Press (OUP)
Volume
28
Issue
9
Pages
2166–2179
Publication date
4 April 2026
Language
EN